MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways Retraction in /10.3892/or.2022.8394

Liu,Xuerong; Wang,Yan; Zhao,Jinglong

doi:10.3892/or.2017.5997

MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways

Retraction in: /10.3892/or.2022.8394

Authors:
- Xuerong Liu
- Yan Wang
- Jinglong Zhao
View Affiliations

Affiliations: Department of Oncology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Hematology, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: September 25, 2017 https://doi.org/10.3892/or.2017.5997
Pages: 3187-3196

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death worldwide. Tumour progression and development in CRC is a multi-step process involving a large number of genetic and epigenetic alterations. Previous studies indicated that abnormally expressed microRNAs play critical roles in CRC through regulation of oncogenic and tumour-suppressor genes. Hence, determination of the function of microRNAs may provide novel therapeutic targets for CRC diagnosis and treatments. MicroRNA‑337 (miR‑337) has been reported to be downregulated in several cancer types. However, the expression, function and underlying mechanisms of miR‑337 in CRC have not been clearly elucidated. In this study, miR‑337 was significantly decreased in CRC tissues and cell lines. Low miR‑337 expression level was correlated with lymph node metastasis, distant metastasis and TNM stage of CRC patients. In addition, upregulation of miR‑337 suppressed cell proliferation and invasion and promoted apoptosis in CRC. Based on bioinformatics analysis, we assumed that Kirsten rat sarcoma viral oncogene homolog (KRAS) was directly modulated by miR‑337 in CRC. Luciferase reporter assay demonstrated the direct interaction between miR‑337 and 3'‑UTR of KRAS mRNA. Furthermore, reverse transcription-quantitative polymerase chain reaction and western blot analysis indicated that miR‑337 could negatively regulate endogenous KRAS expression in CRC cells at both mRNA and protein levels. Moreover, KRAS was highly expressed in CRC tissues and inversely correlated with miR‑337 expression in CRC tissues. KRAS knockdown recapitulates effects similar to those induced by miR‑337 overexpression in CRC cells, whereas KRAS overexpression partially restored the tumour suppressive effects of miR‑337. Besides, ectopic expression of miR‑337 inactivates the AKT and ERK signalling pathways in CRC. These results suggested that miR‑337 may act as a tumour suppressor during the process of CRC malignant transformation by interacting with KRAS.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB and Maisonneuve P: Smoking and colorectal cancer: A meta-analysis. JAMA. 300:2765–2778. 2008. View Article : Google Scholar : PubMed/NCBI
4	Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN and Katzmarzyk PT; Lancet Physical Activity Series Working Group, : Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy. Lancet. 380:219–229. 2012. View Article : Google Scholar : PubMed/NCBI
5	Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI
6	Juez I, Rubio C and Figueras J: Multidisciplinary approach of colorectal liver metastases. Clin Transl Oncol. 13:721–727. 2011. View Article : Google Scholar : PubMed/NCBI
7	Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Xue J, Niu J, Wu J and Wu ZH: MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol. 5:730–743. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tutar L, Tutar E, Özgür A and Tutar Y: Therapeutic targeting of microRNAs in cancer: Future perspectives. Drug Dev Res. 76:382–388. 2015. View Article : Google Scholar : PubMed/NCBI
11	Stahlhut C and Slack FJ: MicroRNAs and the cancer phenotype: Profiling, signatures and clinical implications. Genome Med. 5:1112013. View Article : Google Scholar : PubMed/NCBI
12	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
13	Guo F, Luo Y, Mu YF, Qin SL, Qi Y, Qiu YE and Zhong M: miR-193b directly targets STMN1 and inhibits the malignant phenotype in colorectal cancer. Am J Cancer Res. 6:2463–2475. 2016.PubMed/NCBI
14	Ding L, Zhang S, Xu M, Zhang R, Sui P and Yang Q: MicroRNA-27a contributes to the malignant behavior of gastric cancer cells by directly targeting PH domain and leucine-rich repeat protein phosphatase 2. J Exp Clin Cancer Res. 36:452017. View Article : Google Scholar : PubMed/NCBI
15	Huang L, Li F, Deng P and Hu C: MicroRNA-223 promotes tumor progression in lung cancer A549 cells via activation of the NF-κB signaling pathway. Oncol Res. 24:405–413. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kong Q, Chen XS, Tian T, Xia XY and Xu P: MicroRNA-194 suppresses prostate cancer migration and invasion by downregulating human nuclear distribution protein. Oncol Rep. 37:803–812. 2017. View Article : Google Scholar : PubMed/NCBI
17	Yang F, Li Y, Xu L, Zhu Y, Gao H, Zhen L and Fang L: miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer. Onco Targets Ther. 10:543–550. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
19	Xiang X, Mei H, Zhao X, Pu J, Li D, Qu H, Jiao W, Zhao J, Huang K, Zheng L, et al: miRNA-337-3p suppresses neuroblastoma progression by repressing the transcription of matrix metalloproteinase 14. Oncotarget. 6:22452–22466. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhang R, Leng H, Huang J, Du Y, Wang Y, Zang W, Chen X and Zhao G: miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7. Diagn Pathol. 9:1712014. View Article : Google Scholar : PubMed/NCBI
21	Zhang R, Zheng S, Du Y, Wang Y, Zang W and Zhao G: Levels of HOXB7 and miR-337 in pancreatic ductal adenocarcinoma patients. Diagn Pathol. 9:612014. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chen S, Wang Y, Zhang Y and Wan Y: Low expression of PKCα and high expression of KRAS predict poor prognosis in patients with colorectal cancer. Oncol Lett. 12:1655–1660. 2016.PubMed/NCBI
24	Hubbard PA, Moody CL and Murali R: Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: Emerging therapeutic opportunities. Front Physiol. 5:4782014. View Article : Google Scholar : PubMed/NCBI
25	Calvo F, Agudo-Ibáñez L and Crespo P: The Ras-ERK pathway: Understanding site-specific signaling provides hope of new anti-tumor therapies. BioEssays. 32:412–421. 2010. View Article : Google Scholar : PubMed/NCBI
26	Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, et al: Novel recurrently mutated genes in African American colon cancers. Proc Natl Acad Sci USA. 112:pp. 1149–1154. 2015; View Article : Google Scholar : PubMed/NCBI
27	Bardhan K and Liu K: Epigenetics and colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013. View Article : Google Scholar : PubMed/NCBI
28	Kang X, Wang M, Wang H, Shen X and Guan W: MiR-4282 suppresses proliferation and mobility of human colorectal carcinoma cells by targeting semaphorin 3E. Panminerva Med. 58:197–205. 2016.PubMed/NCBI
29	Fan C, Lin Y, Mao Y, Huang Z, Liu AY, Ma H, Yu D, Maitikabili A, Xiao H, Zhang C, et al: MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2. Oncotarget. 7:21825–21839. 2016. View Article : Google Scholar : PubMed/NCBI
30	Long HC, Gao X, Lei CJ, Zhu B, Li L, Zeng C, Huang JB and Feng JR: miR-542-3p inhibits the growth and invasion of colorectal cancer cells through targeted regulation of cortactin. Int J Mol Med. 37:1112–1118. 2016. View Article : Google Scholar : PubMed/NCBI
31	Wang Z, Wang J, Yang Y, Hao B, Wang R, Li Y and Wu Q: Loss of hsa-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer. J Exp Clin Cancer Res. 32:762013. View Article : Google Scholar : PubMed/NCBI
32	Zheng L, Jiao W, Mei H, Song H, Li D, Xiang X, Chen Y, Yang F, Li H, Huang K, et al: miRNA-337-3p inhibits gastric cancer progression through repressing myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14. Oncotarget. 7:40314–40328. 2016. View Article : Google Scholar : PubMed/NCBI
33	Du L, Subauste MC, DeSevo C, Zhao Z, Baker M, Borkowski R, Schageman JJ, Greer R, Yang CR, Suraokar M, et al: miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers. PLoS One. 7:e391672012. View Article : Google Scholar : PubMed/NCBI
34	Kang HS, Kim J, Jang SG, Kwon SY, Park YS, Green JE, Kim HK and Ro J: MicroRNA signature for HER2-positive breast and gastric cancer. Anticancer Res. 34:3807–3810. 2014.PubMed/NCBI
35	Wu C, Wang C, Guan X, Liu Y, Li D, Zhou X, Zhang Y, Chen X, Wang J, Zen K, et al: Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One. 9:e922922014. View Article : Google Scholar : PubMed/NCBI
36	Zhong N, Sun J, Min Z, Zhao W, Zhang R, Wang W, Tian J, Tian L, Ma J, Li D, et al: MicroRNA-337 is associated with chondrogenesis through regulating TGFBR2 expression. Osteoarthritis Cartilage. 20:593–602. 2012. View Article : Google Scholar : PubMed/NCBI
37	Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, et al: APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology. 131:1096–1109. 2006. View Article : Google Scholar : PubMed/NCBI
38	Li M, Liu W, Zhu YF, Chen YL, Zhang BZ and Wang R: Correlation of COX-2 and K-ras expression to clinical outcome in gastric cancer. Acta Oncol. 45:1115–1119. 2006. View Article : Google Scholar : PubMed/NCBI
39	Przybojewska B, Jagiello A and Jalmuzna P: H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers. Cancer Genet Cytogenet. 121:73–77. 2000. View Article : Google Scholar : PubMed/NCBI
40	de Mello RA, Marques DS, Medeiros R and Araújo AM: Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies. World J Clin Oncol. 2:367–376. 2011. View Article : Google Scholar : PubMed/NCBI
41	Lisiansky V, Naumov I, Shapira S, Kazanov D, Starr A, Arber N and Kraus S: Gene therapy of pancreatic cancer targeting the K-Ras oncogene. Cancer Gene Ther. 19:862–869. 2012. View Article : Google Scholar : PubMed/NCBI
42	Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, Mavroudis D, Georgoulias V and Voutsina A: KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PLoS One. 9:e1049022014. View Article : Google Scholar : PubMed/NCBI
43	Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V and Der CJ: K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 67:2098–2106. 2007. View Article : Google Scholar : PubMed/NCBI